Kyverna Therapeutics logo
Remote hiring company

Remote jobs at Kyverna Therapeutics

Harnessing the power of cell therapy in autoimmune disease.

BiotechnologyHealthcareScience
Company overview

About Kyverna Therapeutics

Kyverna is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience.

Purpose

Mission and direction

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies designed to transform treatment for autoimmune diseases. The company focuses on advancing novel CAR T-cell therapies with the goal of delivering potentially curative options across multiple B-cell-driven and neuroimmunology indications, while improving patient access and experience through next-generation innovation.

How they work

Company values

  • Stay True to Why
  • Collaborate to Accelerate
  • Lead with Clarity
  • Boldly Innovative
  • Own the Outcome